AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C

AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C on FirstWord Pharma.

https://m.firstwordpharma.com/abbvie-receives-us-fda-approval-once-daily-viekira-xr-dasabuvir-ombitasvir-paritaprevir-and

Republicado por:RM Consult